ArticleBulletin of the World Health Organization2011
Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis.
Article in Bulletin of the World Health Organization, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 201 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
201 citing papers in PubMed, 8 syntheses or guidelines pooled it, 405 citations in OpenAlex.
- Management of Adult Bronchiectasis: Consensus-Based Guidelines of the German Respiratory Society.Respiration; international review of thoracic diseases · 2026Guideline
- A Systematic Review of Chronic Pulmonary Aspergillosis Among Patients Treated for Pulmonary Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Pooled it
- Incidence and predictors of pulmonary aspergillosis in patients with lung cancer: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Systematic review and meta-analysis of galactomannan antigen testing in serum and bronchoalveolar lavage for the diagnosis of chronic pulmonary aspergillosis: defining a cutoff.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Pooled it
- Stereotactic body radiotherapy for recurrent hemoptysis due to chronic pulmonary aspergillosis: a case report and systematic review of the literature.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Pooled it
- Risk-Based Estimate of Human Fungal Disease Burden, China.Emerging infectious diseases · 2020Pooled it
- Accuracy of serological tests for diagnosis of chronic pulmonary aspergillosis: A systematic review and meta-analysis.PloS one · 2020Pooled it
- An estimate of the burden of serious fungal diseases in Greece.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Pooled it
- Prospective study of the serum Aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis.BMC infectious diseases · 2019Trial
- Trial
- Economic burden of chronic pulmonary aspergillosis in Uganda: a cost-of-illness analysis.IJID regions · 2026Article
- Clinical impact of chronic pulmonary aspergillosis in patients with pulmonary nontuberculous mycobacterial disease and colonization: a multicentre prospective cohort study.Annals of medicine · 2026Article
- Robotic-Assisted Bronchoscopy and Pulmonary Nodules Due to Atypical Infections in Coccidioidomycosis Endemic Area.CHEST pulmonary · 2026Article
- Pulmonary cavitation as a dominant prognostic indicator in tuberculosis complicated by chronic pulmonary aspergillosis: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Describing the burden and characteristics ofBMJ open respiratory research · 2026Article
- Review of the Microbial Spectrum of Mixed Respiratory Fungal Infections.Journal of epidemiology and global health · 2026Review
- Chronic Pulmonary Aspergillosis in Children: A Scoping Global Review.Open forum infectious diseases · 2026Article
- Performance of the LDBioMicrobiology spectrum · 2026Article
- Hemoptysis in a patient with MDR-tuberculosis: successful diagnosis with photon counting CT and embolization of a Rasmussen aneurysm.Infection · 2026Article
- Association of Diabetes Mellitus and Malnutrition withInfection and drug resistance · 2026Article
141 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo estimate the global burden of chronic pulmonary aspergillosis (CPA) after pulmonary tuberculosis (PTB), specifically in cases with pulmonary cavitation.
methodsPTB rates were obtained from the World Health Organization and a scoping review of the literature was conducted to identify studies on residual pulmonary cavitation after PTB and estimate the global incidence of CPA after PTB. Having established that from 21% (United States of America) to 35% (Taiwan, China) of PTB patients developed pulmonary cavities and that about 22% of these patients developed CPA, the authors applied annual attrition rates of 10%, 15% and 25% to estimate the period prevalence range for CPA over five years. Analysis was based on a deterministic model.
findingsIn 2007, 7.7 million cases of PTB occurred globally, and of them, an estimated 372,000 developed CPA: from 11,400 in Europe to 145,372 in South-East Asia. The global five-year period prevalence was 1,174,000, 852,000 and 1,372,000 cases at 15%, 25% and 10% annual attrition rates, respectively. The prevalence rate ranged from < 1 case per 100,000 population in large western European countries and the United States of America to 42.9 per 100,000 in both the Democratic Republic of the Congo and Nigeria. China and India had intermediate five-year period prevalence rates of 16.2 and 23.1 per 100,000, respectively.
conclusionThe global burden of CPA as a sequel to PTB is substantial and warrants further investigation. CPA could account for some cases of smear-negative PTB. Since CPA responds to long-term antifungal therapy, improved case detection should be urgently undertaken.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.